NCT03517449 2026-03-19
MK-3475-775
Eisai Inc.
Phase 3 Completed
Clinical Trials
261 trialsNCT02195973 2026-02-09
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Completed
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03884101 2026-02-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00980954 2025-12-31
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02001272 2025-12-19
EWOC-1
Hospices Civils de Lyon
Phase 2 Completed
NCT03245892 2025-12-17
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04865289 2025-12-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05613088 2025-10-20
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT05446870 2025-10-01
MK-4830-002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04908787 2025-09-11
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT04374630 2025-09-10
PROFECTA-II
Laekna Limited
Phase 2 Completed
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
NCT02730416 2025-07-29
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT04608409 2025-06-29
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
Phase 1 Completed
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT02520154 2025-06-08
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02713386 2025-05-25
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 1/2 Completed
NCT03603184 2025-05-09
AtTEnd
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT00516724 2025-04-11
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
Phase 1 Completed
NCT00513786 2025-03-28
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02684227 2025-03-19
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT04868708 2025-03-04
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
Phase 2 Completed
NCT01220154 2025-02-21
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04034251 2025-02-03
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT02630823 2025-01-03
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
Phase 1 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT00889382 2024-11-20
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Astellas Pharma Inc
Phase 1/2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03246074 2024-10-24
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03635489 2024-10-03
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03648489 2024-09-20
DICE
Imperial College London
Phase 2 Completed
NCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02501954 2024-07-23
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
Women's Cancer Care Associates, LLC
Phase 3 Completed
NCT03989336 2024-07-15
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Chinese PLA General Hospital
Phase 2 Completed
NCT03126812 2024-05-29
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT02312661 2024-05-06
OVMET
University Medical Center Groningen
Phase 1 Completed
NCT03940196 2024-03-29
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
NovoCure Ltd.
Phase 3 Completed
NCT03189446 2024-03-08
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
University of Oklahoma
Phase 2 Completed
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT02766582 2024-02-26
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed